Relmada Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone. My name is Farzin Haque, one of the biotech analysts at Jefferies. It is my pleasure to introduce Sergio Traversa, Bipin Dalmia, and Maged Shenouda of Relmada. This is the fireside chat format. Maybe to start off, Sergio, can you provide a brief intro to the company and one-minute intro, please?
Sure. Well, thank you, Farzin, and thank you, Jefferies, all for the invitation to participate in your conference. I am Sergio Traversa, the co-founder and CEO of Relmada. As a quick overview of the company, we have been on NASDAQ since 2019. Originally, Relmada was born as a spinoff from Cornell University as a pure CNS company, central nervous system. I have been working in these programs for many years. The CNS is a very attractive space, and we do still have one leg in CNS. We thought about managing the risk profile. CNS is well known for being rather risky, and we expanded to a new area a couple of years ago with the acquisition of the rights of a very interesting, attractive product in bladder cancer, NDV-01, from a company in Israel called Trigone Pharma Ltd.
This clearly has changed quite dramatically the profile of Relmada, with a clear improve in the risk management. NDV-01 is now the short-term or the next 12-18 months focus of the company, and probably also beyond that. The reason is that the risk profile has been lowered and has been managed because the NDV-01 is an extended-release formulation of two well-known chemotherapeutics for cancer, gemcitabine and docetaxel, and called Gem/Doce. This is already used in bladder cancer. Bladder cancer is an interesting area, is a tumor, but is usually, and is not lethal. The treatment is pretty much a chronic treatment and make the market very attractive, including the number of patients is also very high. So NDV-01 is an extended-release formulation of Gem/Doce.
Gem/Doce is already used, but because of the complication of the use, you need a specialty pharmacy, and the treatment takes four or five hours in the doctor office, is kind of used restricted to the university and to the specialized clinic, while 80% of the patient in bladder cancer is treated in the community setting. The extended-release formulation, NDV-01, it changed totally the profile of this treatment. Is administered in, we say, less than 10 minutes. In reality, it is even less than five minutes. In the commercial form, it would be prefilled syringe. It will allow the community treatment of the patient with bladder cancer to use this therapy. That is 80% of the patients. So it is a low risk because it is a clinically known entity.
We discussed the FDA, the development plan that is the two indication for intermediate risk and sorry, second line, the post-BCG unresponsive, and that will be the first indication. The FDA, we agreed on a plan for the development, two known entities, and an extended release that can be administered in a very easy and fast way. That is what we would like to focus the conversation today. Hope I gave you an idea of what Relmada does in two minutes.
Great. Can you size the two opportunities that you just talked about, the high-risk settings and the intermediate risk, intermediate risk?
Sure. One thing that also I would like to mention before I answer your question, we just announced this morning a very important hire for us. We have a new Chief Development Officer that is Jørn, that is the clinician that post formerly at Ferring, I can say that because it is now public, and he is virtually the father, the clinical father of ADSTILADRIN, where he followed the whole development and the global approval of the first viral treatment for bladder cancer. Jørn has worked with Bipin for 10 years at Ferring, so we are very, very happy that we have a new high-profile person will develop this product. I let Bipin to answer your question, as he was the Global Head of Urology and Uro-Oncology at Ferring.
Go ahead, Bipin. Yeah. Thanks, Sergio.
Thank you, Farzin. To size the opportunity, if we just take a step back, in the U.S., I will just focus on the U.S., there is about 85,000 new cases of bladder cancer, non-muscle invasive bladder cancer that is diagnosed each year. Oh, bladder cancer. Of those, 75%, so roughly about 65,000 new patients are diagnosed each year. Because it is a non-lethal cancer in the short term, the prevalent pool is about 600,000. So it is a very large patient population, of which about 40% are high risk, and BCG is used, and then you have BCG unresponsive. In the BCG unresponsive setting, there is roughly about 16,000 patients. That is where all the activity is. There are four drugs approved now in the BCG unresponsive setting, addressing those 16,000 patients. However, the efficacy of those drugs is limited.
And this second-line setting that we are going after, and third line, because our clinical study is for both second and third line setting, that's a growing population. The estimate we have is about 12,000 patients will fail the first line BCG-unresponsive setting and go on an annual basis to second line. But the drug itself, that's our registrational study. Then for the intermediate risk, which is a very recurrent population, that's about 60,000. So our registrational studies will address 12,000 patients in the second line, third line setting, and about 60,000 patients in the intermediate risk setting.
Makes sense. So enGene is developing this non-viral immunotherapy angle, and then you have Tyra, which is also is developing an oral therapy. So where does NDV-01, you have a chemo regimen, so that's used primarily in the community settings, I would imagine. Then, so basically, what would you need to see to basically fit in the treatment landscape?
Right. I'll let Bipin answer this one too as- Yeah.
So in oncology, everything starts with efficacy, right? So you have to have an efficacious drug. But efficacy is a necessary component for success, but it's not sufficient for success. With the explosion of drug development and non-muscle invasive bladder cancer, people are looking at the total product profile. They're looking for efficacy without paying a cost on toxicity or convenience. So you need that balanced profile. So what gives us confidence with the NDV-01 profile, and you've seen that in our phase II data, which we can describe, is we have very high and durable response rates without sacrificing or trading off convenience or tolerability. So it's a very tolerable drug, giving very high efficacy in a drug format that's very easy to use, that opens up the very large community. 80% of patients are treated in the community setting.
The two drugs you mentioned, they will have their own efficacy. Based on the data we've seen, I think the efficacy is limited for one of them, and the other one, it's early days, but we don't want to comment too much on other people's drugs.
Okay. Good. I want to touch on the CMC aspect, because that's what is really gating the phase III start. The phase II product was, it needed like 120-degree centigrade sterilization. Now you're evaluating two different processes. So what are those, and what is the key criteria for choosing between them? Because doce has this thermal sensitivity issue that we are aware of.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
